secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001787306-25-000147
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis appoints Amit Munshi to Board; founder Chaudhuri retires, retains consulting role
--------------------------------------------------------------------------------

- Bhaskar Chaudhuri retired from Board and Compensation Committee chair on Dec 3, 2025; no disagreement.
- Chaudhuri entered consulting agreement through June 30, 2027 with hourly rate; options continue to vest.
- Amit Munshi appointed Class II director and Compensation Committee chair effective Dec 4, 2025.
- Munshi received initial option for 16,502 shares; eligible for prorated annual equity of ~$300,000 and cash retainers of $50,000 (Board) + $15,000 (chair).
- Munshi previously served as CEO of Arena Pharmaceuticals (acquired by Pfizer for $6.7B) and Orna Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000147/0001787306-25-000147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000147/arqt-20251203.htm
  HTML page:      https://secwatch.observer/filing/0001787306-25-000147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer